Anthracycline-induced cardiotoxicity

Annals of Internal Medicine

Volumn 125, Issue 1, 1996, Pages 47-58

  Shan, Kesavan ^a   Michael Lincoff, A ^a   Young, James B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; PRENYLAMINE; PROBUCOL; PROPRANOLOL DERIVATIVE; RAZOXANE;

CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG INDICATION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0030317942     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-1-199607010-00008     Document Type: Article

References (146)

1. Hitchcock-Bryan S, Gelber RD, Cassady JR, Sallan SE. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986;14:211-5.
2. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA. 1996;273:542-7.
3. Fisher B, Redmond C, Wickerham DL, Bowman D, Schipper H, Wolmark N, et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989;7:572-82
4. Ettinghausen SE, Bonow RO, Palmeri ST, Seipp CA, Steinberg SM. White DE, et al. Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. Arch Surg 1986;121:1445-51.
5. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep. 1979;63:827-34.
6. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-7.
7. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-14.
8. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM. Acute armythmogenicity of doxorubicin administration. Cancer. 1987;60:1213-8.
9. Lenaz L, Page JA. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev. 1976;3:111-20.
10. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep. 1978;62:955-61.
11. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977;62:200-8.
12. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978;62:873-9.
13. Friedman MA, Bozdech MJ, Billingham ME, Rider AK. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA. 1978;240:1603-6.
14. Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M, et al. Doxorubicin-induced congestive heart failure in adults Cancer. 1985; 56:1361-5.
15. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109-18.
16. Steinherz U, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991; 266:1672-7.
17. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-15.
18. Yeung ST, Yoong C, Spink J, Galbraith A, Smith PJ. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet. 1991;337:816-8.
19. Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol. 1992;70:73-7.
20. Steinherz U, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol. 1995;24:352-61.
21. Steinherz L, Steinherz P. Delayed cardiac toxicity from anthracycline therapy. Pediatrician. 1991;18:49-52.
22. Goorin AM, Borow KM, Goldman A, Williams RG, Henderson IC, Sallan SE, et al. Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer. 1981;47:2810-6.
23. Moreb JS, Oblon DJ. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer. 1992;70:2637-41.
24. Lewis AB, Crouse VL, Evans W, Takahashi M, Siegel SE. Recovery of left ventricular function following discontinuation of anthracycline chemotherapy in children. Pediatrics. 1981;68:67-72.
25. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133-9.
26. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978;88:168-75.
27. Cortes EP, Lutman G, Wanka J, Wang JJ, Pickren J, Wallace J, et al. Adriamycin (NSC-123127) cardiotoxicity: a clinicopathologic correlation. Cancer Chemother Rep. 1975;6:215-25.
28. Pratt CB, Ransom JL, Evans WE. Age-related adriamycin cardiotoxicity in children. Cancer Treat Rep. 1978;62:1381-5.
29. Cuthbertson DD, Epstein ST, Lipshultz SE, Goorin AM, Epstein ML, Krischer JP. Anthracycline cardiotoxicity in children with cancer [Abstract], Circulation. 1994;90(Suppl):1-50.
30. Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 1983;99:745-9.
31. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol. 1989;7:560-71.
32. Speyer JL, Green MD, Dubin N, Blum RH, Wernz JC, Roses D, et al. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med. 1985;78:555-63.
33. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med. 1978;65.823-32.
34. Leandro J, Dyck J, Poppe D, Shore R, Airhart C, Greenberg M, et al. Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol. 1994;74:1152-5.
35. Jakacki R, Silber J, Larsen R, Barber G, Goldwein J, Meadows A. Cardiac dysfunction following "low risk" cardiotoxic treatment for childhood malignancy [Abstract]. Pediatr Res. 1991;29:143A.
36. LaMonte CS, Yeh SD, Straus DJ. Long-term follow-up of cardiac function in patients with Hodgkin's disease treated with med astinal irradiation and combination chemotherapy including doxorubicin. Cancer Treat Rep. 1986; 70:439-44.
37. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43
38. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol. 1993;21:477-9.
39. Bu'Lock FA, Martin RP, Mott MG. Increased risk of cardiac dysfunction after anthracyclines in girls (Letter). Med Pediatr Oncol. 1995;24:143-4.
40. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A. 1990;87:4275-9.
41. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 1983;43:460-72.
42. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988;48:4766-9
43. Jackson JA, Reeves JP, Muntz KH, Kruk D, Prough RA, Willerson JT, et al. Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol. 1984;117:140-53.
44. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977;197:165-7.
45. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980;65:128-35.
46. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation. 1994;89:2829-35.
47. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation. 1995;91:10-5
48. Singal PK, Siveski-Iliskovic N, Hill M, Thomas IP, LI T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol. 1995;27:1055-63
49. Singal PK, Pierce GN. Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol. 1986; 250(3 Pt 2):H419-25.
50. Olson HM, Young DM, Prieur DJ, LeRoy AF, Reagan RL. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol. 1974;77:439-54.
51. Kusuoka H, Futaki S, Koretsune Y, Kitabatake A, Suga H, Kamada T, et al. Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure. J Cardiovasc Pharmacol. 1991;18:437-44.
52. Holmberg SR, Williams AJ. Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum. Circ Res. 1990;67:272-83.
53. Wang YX, Korth M. Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circ Res. 1995;76:645-53.
54. Wakasugi S, Wada A, Hasegawa Y, Nakano S, Shibata N. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine. J Nucl Med. 1992;33:208-14.
55. Valdes Olmos RA, ten Bokkel Huinink WW, Greve JC, Hoefnagel CA. I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity. Clin Nucl Med. 1992;17:163-7.
56. 123I)metaiodobenzylguanidine scintigraphy. Eur J Cancer. 1995;31A:26-31.
57. Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, et al. Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab Invest. 1981;45:157-68.
58. Bristow MR, Kantrowitz NE, Harrison WD, Minobe WA, Sageman WS, Billingham ME, et al. Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharmacol. 1983;5:913-9.
59. Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, et al. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest. 1995;95:1595-605.
60. Boucek RJ Jr, Olson RO, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem. 1987;262:15851-6.
61. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561-6.
62. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive hear failure. Circulation. 1995;92:1479-86.
63. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 1996: [In press].
64. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest. 1994;105:897-904.
65. Holmberg SR. Gumming DV, Kusama Y, Hearse DJ, Poole-Wilson PA, Shattock MJ, et al. Reactive oxygen species modify the structure and function of the cardiac sarcoplasmic reticulum calcium-release channel. Cardioscience. 1991;2:19-25.
66. Burton KP, Morris AC, Massey KD, Buja LM, Hagler HK. Free radicals alter ionic calcium levels and membrane phospholipids in cultured rat ventricular myocytes. J Mol Cell Cardiol. 1990;22:1035-47.
67. Fujita N, Hiroe M, Ohta Y, Horie T, Hosoda S. Chronic effects of metoprolol on myocardial β-adrenergic receptors in doxorubicin-induced cardiac damage in rats. J Cardiovasc Pharmacol 1991;17:656-61.
68. Robison TW, Giri SN. Effects of chronic administration of doxorubicin on myocardial β-adrenergic receptors. Life Sci. 1986;39:731-6.
69. Tong J, Ganguly PK, Singal PK. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol. 1991;260(3 Pt 2):H909-16.
70. Yoshikawa T, Handa S, Suzuki M, Nagami K. Abnormalities in sympathoneuronal regulation are localized to failing myocardium in rabbit heart. J Am Coll Cardiol. 1994;24:210-5.
71. Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol. 1993;22(4 Suppl A):72A-84A.
72. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. J Am Coll Cardiol. 1993;22(4 Suppl A):146A-53A.
73. Ehrke MJ, Maccubbin D, Ryoyama K, Cohen SA, Mihich E. Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res. 1986;46:54-60.
74. Shi F, MacEwen EG, Kurzman ID. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation. Cancer Res. 1993;53:3986-91
75. Abdul Hamied TA, Parker D, Turk JL. Effects of adriamycin, 4-hydroperoxycyclophosphamide and ASTA Z 7557 (INN mafosfamide) on the release of IL-2 and IL-1 in vitro. Int J Immunopharmacol. 1987;9:355-61
76. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation, 1995;92:1487-93.
77. Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy [Letter]. Lancet. 1990;335:294-5.
78. Beck AC, Ward JH, Hammond EH, Wray RB, Samlowski WE. Cardiomyopathy associated with high-dose interleukin-2 therapy. West J Wed. 1991;155:293-6.
79. Raziuddin S, Sheikha A, Abu-Eshy S, al-Janadi M. Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies. Cancer. 1994;73:2426-31.
80. Elbaz O, Mahmoud LA. Tumor necrosis factor and human acute leukemia. Leuk Lymphoma. 1994;12:191-5.
81. Anastasopoulos E, Reclos GJ, Baxevanis CN, Gritzapis AD, Tsilivakos V, Panagiotopoulos N, et al. Monocyte disorders associated with T cell defects in patients with solid tumors. Anticancer Res. 1992;12:489-94.
82. Sorensen K, Levin G, Sebag-Montefiore D, Bull C, Sullivan I. Cardiac function in Wilms' tumor survivors. J Clin Oncol. 1995;13:1546-56.
83. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993;270:1949-55.
84. Lipshultz SE, Lipsitz SR, Mone SM, Sallan SE, Colan SD. Left ventricular structure and function eleven years after doxorubicin treatment for childhood leukemia: is this a restrictive cardiomyopathic process? [Abstract] J Am Coll Cardiol. 1995;25:54A.
85. Ali MK, Ewer MS, Gibbs HR, Swafford J, Graft KL. Late doxorubicinassociated cardiotoxicity in children. The possible role of intercurrent viral infection. Cancer. 1994;74:182-8.
86. Billingham ME, Bristow MR. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treatment Symposia. 1984;3:71-6.
87. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978;62:857-64.
88. Isner JM, Ferrans VJ, Cohen SR, Witkind BG, Virmani R, Gottdiener JS, et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol. 1983;51:1167-74.
89. Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxcity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J. 1986;55:274-82.
90. Pegelow CH, Popper RW, de Wit SA, King OY, Wilbur JR. Endomyocardial biopsy to monitor anthracycline therapy in children. J Clin Oncol. 1984;2:443-6.
91. Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxtcity with quantitative radionuclide angiocardiography. N Engl J Med. 1979;300:278-83.
92. Piver MS, Marchetti DL, Parthasarathy KL, Bakshi S, Reese P. Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography. Cancer, 1985;56:76-80.
93. Ritchie JL, Singer JW, Thorning D, Sorensen SG, Hamilton GW. Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer. 1980;46:1109-16.
94. Zaret BL, Schwarte PE, Berger HJ, Schwarte RG. Evaluation of doxorubicin cardiotoxicity with radionuclide angiocardiography at rest. Cancer Treatment Symposia. 1984;3:61-6.
95. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J. 1981;102:709-18.
96. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983;106:1048-56.
97. Steinherz U, Graham T, Hurwitz R, Sondheimer HM, Schwarte RG, Shatter EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992;89(5 Pt 1):942-9.
98. Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD, et al. Monitoring for anthracycline cardiotoxicity. Pediatrics. 1994;93:433-37.
99. Steinherz U, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Sandor G, et al. Guidelines for monitoring of anthracycline cardiomyopathy: a rebuttal [letter]. Pediatrics. 1994;94:782-4.
100. Borow KM, Henderson IC, Neuman A, Colan S, Grady S, Papish S, et al. Assessment of left ventricular contractility in patients receiving doxorubicin. Ann Intern Med. 1983;99:750-6.
101. Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989;118:92-8.
102. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987;9:184-8.
103. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992;20:62-9.
104. Ganz WI, Sridhar KS, Forness TJ. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate. Am J Clin Oncol. 1993;16:109-12.
105. Hausdorf G, Morf G, Beron G, Erttmann R, Winkler K, Landbeck G, et al. Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling. Br Heart J. 1988;60:309-15.
106. Ewer MS, Ali MK, Gibbs HR, Swafford J, Graft KL, Cangir A, et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol. 1994;33:545-9.
107. Cottin Y, Touzery C, Coudert B, Gilles A, Walker P, Massing JL, et al. Impairment of diastolic function during short-term anthracycline chemotherapy. Br Heart J. 1995;73:61-4.
108. Schmitt K, Tulzer G, Merl M, Aichhorn G, Grillenberger A, Wiesinger G, et al. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters. Eur J Pediatr. 1995; 154:201-4
109. Klewer SE, Goldberg SJ, Donnerstein RL, Berg RA, Hutter JJ Jr. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol. 1992;19:394-401.
110. Weesner KM, Bledsoe M, Chauvenet A, Wofford M. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer. 1991;68:435-8.
111. Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO, Myers CE, Barr LH, et al. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med. 1981;94(4 Pt 1): 430-5.
112. Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J. 1995;73:340-50.
113. Dell'ltalia U, Freeman GL, Gaasch WH. Cardiac function and functional capacity: implications for the failing heart. Curr Probl Cardiol. 1993;18:705-58.
114. Pai RG, Shah PM. Echocardiographic and other noninvasive measurements of cardiac hemodynamics ventricular function. Curr Probl Cardiol. 1995;20:681-770.
115. Rihal CR, Nishimura RA, Hatle LK, Bailey KR, Tajik AJ. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation. 1994;90:2772-9.
116. Werner GS, Schaefer C, Dirks R, Figulla HC, Kreuzer H. Prognostic value of Doppler echocardiographic assessment of left ventricular filling in idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;73:792-8.
117. Belardinelli R, Georgiou D, Cianci G, Berman N, Ginteon L, Purcaro A. Exercise training improves left ventricular diastolic filling in patients with dilated cardiomyopathy. Clinical and prognostic implications. Circulation. 1995;91:2775-84.
118. Bielack SS, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol. 1989;25:873-82.
119. Treat J, Greenspan A, Forst D, Sanchez JA, Ferrans VJ, Potkul LA, et al. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990;82:1706-10.
120. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992;10:117-27.
121. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988;319:745-52.
122. Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother. 1994;28:1063-72.
123. Kolaric K, Bradamante V, Cervek J, Cieslinska A, Cisarz-Filipcak E, Denisov LE, et al. A phase-II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide. Oncology. 1995;52:251-5.
124. Bu'Lock FA, Gabriel HM, Oakhill A, Mott MG, Martin RP. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J. 1993;70:185-8.
125. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJ. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunoribicin and etoposide (VP-16). Biochem Pharmacol. 1993;46:389-93.
126. Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, et al. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol. 1980;2:487-515.
127. Wikman-Coffelt J, Rapcsak M, Sievers R, Rouleau JL, Parmley WW. Verapamil, propranolol, and hydralazine protect against the acute cardiac depression induced by adriamycin. Cardiovasc Res. 1983;17:43-9.
128. Santostasi G, Kutty RK, Krishna G. Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes. Toxicol Appl Pharmacol, 1991;108:140-9.
129. Akimoto H, Bruno NA, Slate DL, Billingham ME, Torti SV, Torti FM. Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes. Cancer Res. 1993;53:4658-64.
130. Milei J, Marantz A, Ale J, Vazquez A, Buceta JE. Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study. Cancer Drug Deliv. 1987;4:129-36.
131. Fu LX, Bergh CH, Hoebeke J, Liang QM, Sjogren KG, Waagstein F, et al. Effect of metoprolol on activity of β-adrenoceptor coupled to guanine nucleotide binding regulatory proteins in adriamycin-induced cardiotoxicity. Basic Res Cardiol. 1991;86:117-26.
132. Mak IT, Weglicki WB. Protection by beta-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circ Res. 1988;63:262-6.
133. Kramer JH, Mak IT, Freedman AM, Weglicki WB. Propranolol reduces anoxia/reoxygenation-mediated injury of adult myocytes through an anti-radical mechanism. J Mol Cell Cardiol. 1991;23:1231-44.
134. Liu XK, Engelman RM, Agrawal HR, Das DK. Preservation of membrane phospholipids by propranolol, pindolol, and metoprolol: a novel mechanism of action of beta-blockers. J Mol Cell Cardiol. 1991;23:1091-100.
135. Shaddy RE, Olsen SL, Bristow MR, Taylor DO, Bullock EA, Tani LY, et al. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J. 1995;129:197-9.
136. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441-6.
137. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994;23:943-50.
138. Bleyer WA. The impact of childhood cancer in the United States and the world. CA Cancer J Clin. 1990;40:355-67.
139. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995;45:8-30.
140. Effect of enalapril on survival in patients with reduced left ventricular fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302.
141. Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA. 1994;271:1276-80.
142. Dorent R, Pavie A, Nataf P, Tedy G, Vaissier E, Ghoussoub JJ, et al. Heart transplantation is a valid therapeutic option for anthracycline cardiomyopathy. Transplant Proc. 1995;27:1683.
143. Armitage JM, Kormos RL, Griffith BP, Flicker FJ, Hardesty RL. Heart transplantation in patients with malignant disease. J Heart Transplant. 1990;9:627-9.
144. Edwards BS, Hunt SA, Fowler MB, Valantine HA, Stinson EB, Schroeder JS. Cardiac transplantation in patients with preexisting neoplastic diseases. Am J Cardiol. 1990;65:501-4.
145. Lee TH, Goldman L. Development and analysis of observational data bases. J Am Coll Cardiol. 1989;14:44A-7A.
146. Diamond GA. Future imperfect: the limitations of clinical prediction models and the limits of clinical prediction. J Am Coll Cardiol. 1989;14:12A-22A.